25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Acrivon Therapeutics, Inc. Common Stock
Buy, Hold or Sell?

Let's analyze Acrivon together

I guess you are interested in Acrivon Therapeutics, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Acrivon Therapeutics, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Acrivon Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Acrivon Therapeutics, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Acrivon (30 sec.)










1.2. What can you expect buying and holding a share of Acrivon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.17
Expected worth in 1 year
$5.90
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$0.73
Return On Investment
11.0%

For what price can you sell your share?

Current Price per Share
$6.65
Expected price per share
$5.5 - $8.74
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acrivon (5 min.)




Live pricePrice per Share (EOD)
$6.65

2.2. Growth of Acrivon (5 min.)




Is Acrivon growing?

Current yearPrevious yearGrowGrow %
How rich?$196.8m$154.5m$5.9m3.7%

How much money is Acrivon making?

Current yearPrevious yearGrowGrow %
Making money-$19.2m-$11.8m-$7.3m-38.4%
Net Profit Margin-255.5%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Acrivon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acrivon?

Welcome investor! Acrivon's management wants to use your money to grow the business. In return you get a share of Acrivon.

First you should know what it really means to hold a share of Acrivon. And how you can make/lose money.

Speculation

The Price per Share of Acrivon is $6.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acrivon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acrivon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.17. Based on the TTM, the Book Value Change Per Share is $0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $1.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acrivon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.59-8.9%-0.56-8.5%-0.40-6.0%-0.39-5.9%-0.39-5.9%
Usd Book Value Change Per Share-0.81-12.2%0.182.7%1.4822.2%0.436.5%0.436.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.81-12.2%0.182.7%1.4822.2%0.436.5%0.436.5%
Usd Price Per Share7.00-6.22-11.68-5.97-5.97-
Price to Earnings Ratio-2.97--2.78--7.55--3.44--3.44-
Price-to-Total Gains Ratio-8.62--8.05--25.14--16.59--16.59-
Price to Book Ratio1.35-1.41-2.36-1.26-1.26-
Price-to-Total Gains Ratio-8.62--8.05--25.14--16.59--16.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.65
Number of shares150
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.180.43
Usd Total Gains Per Share0.180.43
Gains per Quarter (150 shares)27.3864.59
Gains per Year (150 shares)109.52258.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101101000258248
202192100517506
303293200775764
40438430010331022
50548540012921280
60657650015501538
70767760018081796
80876870020672054
90986980023252312
10010951090025842570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.09.01.016.7%2.09.01.016.7%2.09.01.016.7%2.09.01.016.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share1.03.00.025.0%2.09.01.016.7%2.09.01.016.7%2.09.01.016.7%2.09.01.016.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Acrivon Therapeutics, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.8130.183-545%1.475-155%0.431-289%0.431-289%
Book Value Per Share--5.1674.627+12%4.964+4%2.850+81%2.850+81%
Current Ratio--12.75312.7670%19.701-35%17.983-29%17.983-29%
Debt To Asset Ratio--0.0830.093-11%0.068+23%0.500-83%0.500-83%
Debt To Equity Ratio--0.0900.104-13%0.073+25%0.059+54%0.059+54%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--436396917.000348903057.700+25%487929824.750-11%418416441.225+4%418416441.225+4%
Eps---0.589-0.564-4%-0.402-32%-0.391-34%-0.391-34%
Ev To Ebitda Ratio---4.340-4.115-5%-9.065+109%-6.590+52%-6.590+52%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.481-0.470-2%-0.321-33%-0.334-30%-0.334-30%
Free Cash Flow To Equity Per Share---0.5200.357-246%0.503-203%0.482-208%0.482-208%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap207056395.000-29%266735917.000213030057.700+25%363749824.750-27%192259960.817+39%192259960.817+39%
Net Profit Margin----2.5550%-0%-0.8520%-0.8520%
Operating Margin----2.7940%-0%-0.9310%-0.9310%
Operating Ratio---2.794-100%-0%0.931-100%0.931-100%
Pb Ratio1.287-5%1.3551.413-4%2.356-43%1.256+8%1.256+8%
Pe Ratio-2.823+5%-2.972-2.781-6%-7.545+154%-3.442+16%-3.442+16%
Price Per Share6.650-5%7.0006.218+13%11.683-40%5.967+17%5.967+17%
Price To Free Cash Flow Ratio-3.459+5%-3.642-3.329-9%-9.135+151%-4.155+14%-4.155+14%
Price To Total Gains Ratio-8.185+5%-8.615-8.047-7%-25.140+192%-16.593+93%-16.593+93%
Quick Ratio--22.36922.088+1%34.276-35%24.791-10%24.791-10%
Return On Assets---0.105-0.116+11%-0.073-30%-0.085-18%-0.085-18%
Return On Equity---0.114-0.128+12%-0.078-31%-0.069-40%-0.069-40%
Total Gains Per Share---0.8130.183-545%1.475-155%0.431-289%0.431-289%
Usd Book Value--196892000.000160531000.000+23%154569250.000+27%94215916.667+109%94215916.667+109%
Usd Book Value Change Per Share---0.8130.183-545%1.475-155%0.431-289%0.431-289%
Usd Book Value Per Share--5.1674.627+12%4.964+4%2.850+81%2.850+81%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--436396917.000348903057.700+25%487929824.750-11%418416441.225+4%418416441.225+4%
Usd Eps---0.589-0.564-4%-0.402-32%-0.391-34%-0.391-34%
Usd Free Cash Flow---18312000.000-15941750.000-13%-10004250.000-45%-10852166.667-41%-10852166.667-41%
Usd Free Cash Flow Per Share---0.481-0.470-2%-0.321-33%-0.334-30%-0.334-30%
Usd Free Cash Flow To Equity Per Share---0.5200.357-246%0.503-203%0.482-208%0.482-208%
Usd Market Cap207056395.000-29%266735917.000213030057.700+25%363749824.750-27%192259960.817+39%192259960.817+39%
Usd Price Per Share6.650-5%7.0006.218+13%11.683-40%5.967+17%5.967+17%
Usd Profit---22441000.000-19244250.000-14%-11853000.000-47%-12547416.667-44%-12547416.667-44%
Usd Revenue---471000.000-100%-0%157000.000-100%157000.000-100%
Usd Total Gains Per Share---0.8130.183-545%1.475-155%0.431-289%0.431-289%
 EOD+3 -5MRQTTM+17 -17YOY+7 -255Y+12 -2210Y+12 -22

3.3 Fundamental Score

Let's check the fundamental score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.823
Price to Book Ratio (EOD)Between0-11.287
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than122.369
Current Ratio (MRQ)Greater than112.753
Debt to Asset Ratio (MRQ)Less than10.083
Debt to Equity Ratio (MRQ)Less than10.090
Return on Equity (MRQ)Greater than0.15-0.114
Return on Assets (MRQ)Greater than0.05-0.105
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.470
Ma 20Greater thanMa 507.116
Ma 50Greater thanMa 1007.466
Ma 100Greater thanMa 2007.781
OpenGreater thanClose6.450
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-20 22:19:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acrivon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-255.5%+255.5%
TTM-255.5%YOY--255.5%
TTM-255.5%5Y-85.2%-170.3%
5Y-85.2%10Y-85.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.4%+109.4%
TTM-255.5%-221.4%-34.1%
YOY--208.7%+208.7%
5Y-85.2%-346.2%+261.0%
10Y-85.2%-470.4%+385.2%
4.3.1.2. Return on Assets

Shows how efficient Acrivon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • -10.5% Return on Assets means that Acrivon generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is -10.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-11.6%+1.1%
TTM-11.6%YOY-7.3%-4.3%
TTM-11.6%5Y-8.5%-3.0%
5Y-8.5%10Y-8.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.5%-11.6%+1.1%
TTM-11.6%-12.0%+0.4%
YOY-7.3%-11.2%+3.9%
5Y-8.5%-12.6%+4.1%
10Y-8.5%-14.2%+5.7%
4.3.1.3. Return on Equity

Shows how efficient Acrivon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • -11.4% Return on Equity means Acrivon generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is -11.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.4%TTM-12.8%+1.4%
TTM-12.8%YOY-7.8%-5.0%
TTM-12.8%5Y-6.9%-5.9%
5Y-6.9%10Y-6.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.4%-14.5%+3.1%
TTM-12.8%-16.0%+3.2%
YOY-7.8%-14.6%+6.8%
5Y-6.9%-18.6%+11.7%
10Y-6.9%-19.3%+12.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Acrivon Therapeutics, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acrivon is operating .

  • Measures how much profit Acrivon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-279.4%+279.4%
TTM-279.4%YOY--279.4%
TTM-279.4%5Y-93.1%-186.2%
5Y-93.1%10Y-93.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--203.3%+203.3%
TTM-279.4%-316.3%+36.9%
YOY--216.5%+216.5%
5Y-93.1%-378.6%+285.5%
10Y-93.1%-480.3%+387.2%
4.3.2.2. Operating Ratio

Measures how efficient Acrivon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.794-2.794
TTM2.794YOY-+2.794
TTM2.7945Y0.931+1.862
5Y0.93110Y0.9310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM2.7943.198-0.404
YOY-3.263-3.263
5Y0.9314.651-3.720
10Y0.9316.419-5.488
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Acrivon Therapeutics, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acrivon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.75 means the company has $12.75 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 12.753. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.767. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.753TTM12.767-0.014
TTM12.767YOY19.701-6.935
TTM12.7675Y17.983-5.216
5Y17.98310Y17.9830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7533.601+9.152
TTM12.7673.872+8.895
YOY19.7014.655+15.046
5Y17.9835.973+12.010
10Y17.9836.258+11.725
4.4.3.2. Quick Ratio

Measures if Acrivon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Quick Ratio of 22.37 means the company can pay off $22.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 22.369. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.088. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ22.369TTM22.088+0.281
TTM22.088YOY34.276-12.188
TTM22.0885Y24.791-2.703
5Y24.79110Y24.7910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.3693.093+19.276
TTM22.0883.416+18.672
YOY34.2764.393+29.883
5Y24.7915.954+18.837
10Y24.7916.436+18.355
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Acrivon Therapeutics, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acrivon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acrivon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Acrivon assets are financed with 8.3% credit (debt) and the remaining percentage (100% - 8.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.083. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.093. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.083TTM0.093-0.010
TTM0.093YOY0.068+0.026
TTM0.0935Y0.500-0.406
5Y0.50010Y0.5000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0830.345-0.262
TTM0.0930.346-0.253
YOY0.0680.311-0.243
5Y0.5000.365+0.135
10Y0.5000.382+0.118
4.5.4.2. Debt to Equity Ratio

Measures if Acrivon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.0% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.090. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.104. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.090TTM0.104-0.013
TTM0.104YOY0.073+0.031
TTM0.1045Y0.059+0.045
5Y0.05910Y0.0590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0900.393-0.303
TTM0.1040.431-0.327
YOY0.0730.384-0.311
5Y0.0590.452-0.393
10Y0.0590.497-0.438
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acrivon generates.

  • Above 15 is considered overpriced but always compare Acrivon to the Biotechnology industry mean.
  • A PE ratio of -2.97 means the investor is paying $-2.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is -2.823. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.972. Based on the earnings, the company is expensive. -2
  • The TTM is -2.781. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.823MRQ-2.972+0.149
MRQ-2.972TTM-2.781-0.191
TTM-2.781YOY-7.545+4.764
TTM-2.7815Y-3.442+0.661
5Y-3.44210Y-3.4420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.823-2.259-0.564
MRQ-2.972-2.480-0.492
TTM-2.781-3.148+0.367
YOY-7.545-3.244-4.301
5Y-3.442-5.991+2.549
10Y-3.442-6.692+3.250
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is -3.459. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.642. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.329. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.459MRQ-3.642+0.182
MRQ-3.642TTM-3.329-0.313
TTM-3.329YOY-9.135+5.806
TTM-3.3295Y-4.155+0.826
5Y-4.15510Y-4.1550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.459-2.995-0.464
MRQ-3.642-3.289-0.353
TTM-3.329-3.668+0.339
YOY-9.135-4.472-4.663
5Y-4.155-8.001+3.846
10Y-4.155-9.190+5.035
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acrivon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.35 means the investor is paying $1.35 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is 1.287. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.355. Based on the equity, the company is underpriced. +1
  • The TTM is 1.413. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.287MRQ1.355-0.068
MRQ1.355TTM1.413-0.058
TTM1.413YOY2.356-0.944
TTM1.4135Y1.256+0.156
5Y1.25610Y1.2560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2872.001-0.714
MRQ1.3552.054-0.699
TTM1.4132.385-0.972
YOY2.3562.431-0.075
5Y1.2563.690-2.434
10Y1.2564.307-3.051
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acrivon Therapeutics, Inc. Common Stock.

4.8.1. Institutions holding Acrivon Therapeutics, Inc. Common Stock

Institutions are holding 75.978% of the shares of Acrivon Therapeutics, Inc. Common Stock.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30RA Capital Management, LLC26.9290.63988340508353000073.381
2024-09-30Perceptive Advisors LLC17.30860.7939536085800
2024-09-30Sands Capital Ventures, LLC6.85334.1764212260500
2024-06-30Citadel Advisors Llc6.84370.0025211964646918928.4278
2024-06-30Marshall Wace Asset Management Ltd3.06360.007494886635139758.8143
2024-06-30Wellington Management Company LLP2.86750.000988813000
2024-06-30BlackRock Inc2.47650.0001767020231193.1078
2024-09-30Vanguard Group Inc2.05840.0001637538-107972-14.483
2024-06-30Geode Capital Management, LLC0.99570.00023083936554726.9912
2024-06-30State Street Corp0.57690.00011786634538734.0549
2024-06-30Dafna Capital Management LLC0.39180.1682121351-10000-7.6132
2024-09-30Charles Schwab Investment Management Inc0.37530.0002116253-27705-19.2452
2024-09-30Northern Trust Corp0.34030.0001105398-8655-7.5886
2024-06-30UBS O'Connor LLC0.33980.0346105249-21700-17.0935
2024-06-30Bridgeway Capital Management, LLC0.18780.00795818100
2024-09-30Baker Bros Advisors LP0.17080.00385288500
2024-09-30Renaissance Technologies Corp0.14820.000545900-8600-15.7798
2024-06-30Exchange Traded Concepts, LLC0.13840.006342864-13336-23.7295
2024-06-30Bank of New York Mellon Corp0.11830366321221950.0512
2024-06-30Morgan Stanley - Brokerage Accounts0.1114034498120.0348
Total 72.29535.84322391438+4298902+19.2%

4.9.2. Funds holding Acrivon Therapeutics, Inc. Common Stock

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30HBM Healthcare Investments AG Ord1.82950.188256665100
2024-10-31Vanguard Total Stock Mkt Idx Inv1.25080.000238740700
2024-10-31iShares Russell 2000 ETF0.91030.0033281951-630-0.2229
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.53020.0011164214-186362-53.1588
2024-08-31Fidelity Small Cap Index0.38520.0042119298-2986-2.4419
2024-10-31iShares Russell 2000 Value ETF0.37260.007511540800
2024-09-30Fidelity Extended Market Index0.25580.001379231-31133-28.2094
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.21150.001265500-2400-3.5346
2024-10-31Schwab US Small-Cap ETF™0.21090.0036531600
2024-06-30Bridgeway Ultra-Small Company Market0.18730.20065800000
2024-10-31Vanguard Russell 2000 ETF0.17420.003553945-340-0.6263
2024-09-30BlackRock Extended Equity Market K0.1390.00243059-18-0.0418
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.09690.00253000000
2024-09-30Schwab Small Cap Index0.0910.00312819200
2024-10-31iShares Micro-Cap ETF0.0890.02452755000
2024-09-30NT R2000 Index Fund - NL0.08450.002826168-2333-8.1857
2024-09-30Fidelity Total Market Index0.08130.00022516918798.0678
2024-09-30Northern Trust Russell 2000 Value Index0.07950.00652463800
2024-09-30NT R2000 Value Index Fund - L0.07950.00642463800
2024-09-30iShares Russell 2000 Small-Cap Idx Instl0.07840.00322428100
Total 7.13740.46532210616-224323-10.1%

5.3. Insider Transactions

Insiders are holding 22.387% of the shares of Acrivon Therapeutics, Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-11Perceptive Advisors LlcBUY23530008.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -302219-8313-7051-19801782



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets214,684
Total Liabilities17,792
Total Stockholder Equity196,892
 As reported
Total Liabilities 17,792
Total Stockholder Equity+ 196,892
Total Assets = 214,684

Assets

Total Assets214,684
Total Current Assets188,984
Long-term Assets25,700
Total Current Assets
Cash And Cash Equivalents 43,415
Short-term Investments 144,038
Other Current Assets 1,531
Total Current Assets  (as reported)188,984
Total Current Assets  (calculated)188,984
+/-0
Long-term Assets
Property Plant Equipment 8,467
Long Term Investments 15,390
Long-term Assets Other 1,843
Long-term Assets  (as reported)25,700
Long-term Assets  (calculated)25,700
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,819
Long-term Liabilities2,973
Total Stockholder Equity196,892
Total Current Liabilities
Short-term Debt 1,040
Accounts payable 1,506
Other Current Liabilities 12,273
Total Current Liabilities  (as reported)14,819
Total Current Liabilities  (calculated)14,819
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,973
Long-term Liabilities  (as reported)2,973
Long-term Liabilities  (calculated)2,973
+/-0
Total Stockholder Equity
Common Stock31
Retained Earnings -174,145
Accumulated Other Comprehensive Income 782
Other Stockholders Equity 370,224
Total Stockholder Equity (as reported)196,892
Total Stockholder Equity (calculated)196,892
+/-0
Other
Capital Stock31
Cash and Short Term Investments 187,453
Common Stock Shares Outstanding 38,105
Liabilities and Stockholders Equity 214,684
Net Debt -39,402
Net Invested Capital 196,892
Net Working Capital 174,165
Property Plant and Equipment Gross 10,126
Short Long Term Debt Total 4,013



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-03-31
> Total Assets 
0
0
106,587
0
94,996
87,713
181,226
170,197
160,049
151,092
138,265
120,521
230,585
214,684
214,684230,585120,521138,265151,092160,049170,197181,22687,71394,9960106,58700
   > Total Current Assets 
0
100,408
100,408
87,162
87,162
78,672
127,751
123,963
153,282
144,492
129,692
112,143
182,358
188,984
188,984182,358112,143129,692144,492153,282123,963127,75178,67287,16287,162100,408100,4080
       Cash And Cash Equivalents 
0
0
99,603
0
83,861
32,080
29,519
27,489
38,074
29,859
36,015
24,607
46,006
43,415
43,41546,00624,60736,01529,85938,07427,48929,51932,08083,861099,60300
       Short-term Investments 
0
0
0
0
0
44,743
98,232
92,723
112,880
112,231
91,443
85,368
134,531
144,038
144,038134,53185,36891,443112,231112,88092,72398,23244,74300000
       Other Current Assets 
0
0
805
0
3,301
1,849
4,344
3,751
2,328
2,402
2,234
2,168
1,821
1,531
1,5311,8212,1682,2342,4022,3283,7514,3441,8493,301080500
   > Long-term Assets 
0
0
6,179
0
7,834
9,041
53,475
46,234
6,767
6,600
8,573
8,378
48,227
25,700
25,70048,2278,3788,5736,6006,76746,23453,4759,0417,83406,17900
       Property Plant Equipment 
0
5,791
5,791
7,222
7,222
7,109
6,862
6,571
6,359
6,189
7,908
7,613
7,443
8,467
8,4677,4437,6137,9086,1896,3596,5716,8627,1097,2227,2225,7915,7910
       Long Term Investments 
0
0
0
0
0
0
41,881
39,275
0
0
0
0
39,895
15,390
15,39039,895000039,27541,881000000
       Other Assets 
0
388
388
612
612
1,932
388
0
408
0
0
0
0
0
0000040803881,9326126123883880
       Deferred Long Term Asset Charges 
0
0
0
0
0
1,544
0
0
0
0
0
0
0
0
000000001,54400000
> Total Liabilities 
0
0
130,396
0
131,572
133,329
10,751
9,728
10,865
12,943
17,070
12,542
14,527
17,792
17,79214,52712,54217,07012,94310,8659,72810,751133,329131,5720130,39600
   > Total Current Liabilities 
0
2,914
2,914
4,452
4,452
6,391
6,516
5,682
7,017
9,299
13,303
9,041
11,284
14,819
14,81911,2849,04113,3039,2997,0175,6826,5166,3914,4524,4522,9142,9140
       Short-term Debt 
0
0
664
0
706
717
726
740
753
776
1,754
944
1,956
1,040
1,0401,9569441,754776753740726717706066400
       Accounts payable 
0
964
964
1,902
1,902
1,976
904
1,374
1,267
1,504
5,048
2,056
1,261
1,506
1,5061,2612,0565,0481,5041,2671,3749041,9761,9021,9029649640
       Other Current Liabilities 
0
66
1,220
0
1,844
3,698
4,817
3,568
4,997
5,515
6,501
6,041
8,067
12,273
12,2738,0676,0416,5015,5154,9973,5684,8173,6981,84401,220660
   > Long-term Liabilities 
0
0
127,482
0
127,120
126,938
4,235
4,046
3,848
3,644
3,767
3,501
3,243
2,973
2,9733,2433,5013,7673,6443,8484,0464,235126,938127,1200127,48200
       Deferred Long Term Asset Charges 
0
0
0
0
0
1,544
0
0
0
0
0
0
0
0
000000001,54400000
       Warrants
0
0
0
0
0
245,036
0
0
0
0
0
0
0
0
00000000245,03600000
       Deferred Long Term Liability 
0
0
0
224
224
1,544
0
0
0
0
0
0
0
0
000000001,544224224000
> Total Stockholder Equity
0
0
-23,809
0
-36,576
-45,616
170,475
160,469
149,184
138,149
121,195
107,979
216,058
196,892
196,892216,058107,979121,195138,149149,184160,469170,475-45,616-36,5760-23,80900
   Common Stock
0
2
2
4
2
2
22
22
22
22
23
23
31
31
3131232322222222224220
   Retained Earnings Total Equity000000-68,788-56,032-47,10300000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-133
-95
9
-427
-302
-83
-70
-19
782
782-19-70-83-302-4279-95-13300000
   Capital Surplus 
0
0
0
0
0
1,618
226,580
229,226
0
0
0
0
0
0
000000229,226226,5801,61800000
   Treasury Stock00000000000000
   Other Stockholders Equity 
0
0
1,054
0
1,327
-120,900
226,580
229,226
232,291
235,597
237,675
240,932
367,750
370,224
370,224367,750240,932237,675235,597232,291229,226226,580-120,9001,32701,05400



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-536
Gross Profit-536-536
 
Operating Income (+$)
Gross Profit-536
Operating Expense-66,701
Operating Income-67,237-67,237
 
Operating Expense (+$)
Research Development45,488
Selling General Administrative21,079
Selling And Marketing Expenses134
Operating Expense66,70166,701
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-67,237
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-60,388-74,086
EBIT - interestExpense = -60,388
-60,388
-60,388
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-60,388-60,388
Earnings Before Interest and Taxes (EBITDA)-59,852
 
After tax Income (+$)
Income Before Tax-60,388
Tax Provision-0
Net Income From Continuing Ops-50,065-60,388
Net Income-60,388
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,237
Total Other Income/Expenses Net6,8490
 

Technical Analysis of Acrivon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acrivon. The general trend of Acrivon is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acrivon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acrivon Therapeutics, Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.6925 < 7.82 < 8.74.

The bearish price targets are: 6.1097 > 5.7 > 5.5.

Tweet this
Acrivon Therapeutics, Inc. Common Stock Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acrivon Therapeutics, Inc. Common Stock. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acrivon Therapeutics, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acrivon Therapeutics, Inc. Common Stock. The current macd is -0.26535821.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acrivon price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Acrivon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Acrivon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acrivon Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartAcrivon Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acrivon Therapeutics, Inc. Common Stock. The current adx is 22.64.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Acrivon shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Acrivon Therapeutics, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acrivon Therapeutics, Inc. Common Stock. The current sar is 7.725584.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Acrivon Therapeutics, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acrivon Therapeutics, Inc. Common Stock. The current rsi is 40.47. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Acrivon Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acrivon Therapeutics, Inc. Common Stock. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acrivon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Acrivon Therapeutics, Inc. Common Stock Daily Stochastic Oscillator ChartAcrivon Therapeutics, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acrivon Therapeutics, Inc. Common Stock. The current cci is -62.16230225.

Acrivon Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acrivon Therapeutics, Inc. Common Stock. The current cmo is -21.76565985.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Acrivon Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartAcrivon Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acrivon Therapeutics, Inc. Common Stock. The current willr is -68.40905104.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Acrivon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Acrivon Therapeutics, Inc. Common Stock Daily Williams %R ChartAcrivon Therapeutics, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acrivon Therapeutics, Inc. Common Stock.

Acrivon Therapeutics, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acrivon Therapeutics, Inc. Common Stock. The current atr is 0.45107361.

Acrivon Therapeutics, Inc. Common Stock Daily Average True Range (ATR) ChartAcrivon Therapeutics, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acrivon Therapeutics, Inc. Common Stock. The current obv is 36,571,874.

Acrivon Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) ChartAcrivon Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acrivon Therapeutics, Inc. Common Stock. The current mfi is 38.70.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acrivon Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acrivon Therapeutics, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Acrivon Therapeutics, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.470
Ma 20Greater thanMa 507.116
Ma 50Greater thanMa 1007.466
Ma 100Greater thanMa 2007.781
OpenGreater thanClose6.450
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Acrivon with someone you think should read this too:
  • Are you bullish or bearish on Acrivon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acrivon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acrivon Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Acrivon Therapeutics, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Acrivon Therapeutics, Inc. Common Stock.

Receive notifications about Acrivon Therapeutics, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.